LAUSR

with insulin only (2/106) or in combination with insulin and metformin (16/106), whereas no patient received these drugs as a monotherapy. Accordingly, the results on metformin and insulin ever ‐ use rate could not have been influenced by these figures. Moreover, as this is a retrospective study with the data originating from 1999 onwards, the newly updated American Diabetes Association recommendations 5 have had less influence on the choice of treatment in the cohort. Theletterwriterspoint outthat thepancreatictissue damagethat can occur as a complication of pancreatitis (pancreatic ductal changes, pseudocysts, etc.) might be a predictor of PPDM, which we concur with. Moreover, in the context of what we already reported as the study's limitations, one of the approaches to assess this hypothesis might include endoscopic procedures in a prediction model as a proxy for pancreatic duct strictures and intraductal stones. This will hope-fully stimulate further studies to explore the abovementioned association. In conclusion, our findings emphasize the importance of con-ducting prospective studies that address the limitations and challenges in diagnosing and managing diabetes in patients with chronic pancreatitis, ultimately leading to improved patient outcomes.